Kymera Therapeutics announced a significant collaboration with Gilead Sciences to develop molecular glue degraders targeting CDK2 in solid tumors, including breast cancer. The deal potentially provides Kymera up to $750 million with $85 million upfront. Concurrently, Sanofi is advancing a different IRAK4 degrader candidate while discontinuing its lead asset with Kymera. These partnerships position Kymera at the forefront of targeted protein degradation in oncology.